Columbus, Georgia-based Aflac Incorporated (AFL) engages in the provision of supplemental health and life insurance products in the United States and Japan. With a market cap of $56.1 billion, the company operates in two segments: Aflac Japan and Aflac U.S. 

Companies valued at $10 billion or more are generally labelled as “large-cap” stocks, and Aflac fits this description perfectly. The American insurance company is the largest provider of supplemental health insurance in the United States. AFL sells its products through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. 

Aflac stock has declined 10.2% from its 52-week high of $115.50. Over the last three months, AFL stock has dipped 4%, underperforming the iShares U.S. Insurance ETF’s (IAK) 1.5% gain.

Longer term, shares of Aflac have risen marginally on a YTD basis, whereas IAK has returned 7.7%. Additionally, AFL stock has soared 17.4% over the past 52 weeks, lagging behind IAK’s 18.8% surge over the same time frame. 

The stock has been trading below its 50-day and 200-day moving averages since mid-May.

Shares of Aflac tumbled 4.8% following the release of its weaker-than-expected Q1 2025 results on Apr. 30. The company reported quarterly revenue of $3.4 billion, down 37.5% year-over-year, primarily due to net investment losses of $963 million. The figure also fell short of Wall Street expectations. Its adjusted EPS stood at $1.66, slightly below the consensus estimate of $1.68. 

In comparison, rival MetLife, Inc. (MET) has performed weaker than AFL stock. MET stock is down 2.4% on a YTD basis while it has surged 14.1% over the past 52 weeks.

Due to AFL’s underperformance relative to its industry peers, analysts are cautious about its prospects. AFL has a consensus rating of “Hold” from the 16 analysts covering the stock. As of writing, the stock is trading slightly below the mean price target of $104.71.